Aetna Choice POS II
Aetna HMO
Aetna Whole Health Banner Health Network
BCBS Arizona BlueAlliance Network
BCBS Blue Card PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
First Health PPO
Great West PPO
Health Net Arizona HMO
Health Net Arizona HMO ExcelCare Network
Health Net Arizona PPO/POS
Humana ChoiceCare Network PPO
Multiplan PHCS PPO
Multiplan PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Duke Cancer Institute's Dr. Neil Spector Discusses The Future of Cancer Care
In a recent talk at Teer House in Durham, North Carolina, Duke Cancer Institute oncologist Neil Spector, MD, talks about the future of cancer care.
Dr. Neil Spector Discusses the Systemic Nature of Cancer
Neil L. Spector, MD, co-director, Experimental Therapeutics, Duke Cancer Institute, Duke University Medical Center, Durham, North Carolina, explains that specialists have a tendency to over simplify cancer, which is a very systemic disease that varies depending on the location and tumor type.
The cancer cells contain specific gene mutations while the area around tumor and metastatic extensions carry different molecular characteristics. Spector describes it as the seed versus the soil, where the tumor is the seed and the soil is the surrounding microenvironment.
The molecular differences observed between the tumor and microenvironment may lead to treatment resistance and are further echoed by those seen in the primary tumor and metastatic sites. The molecular profile can vary systemically, which can greatly affect the treatment paradigm.
Each of these molecular differences makes cancer extremely complex. Determining the systemic differences using molecular analysis will help researchers develop therapies and combinations of therapies that can have a dramatic break-through effect on the treatment of cancer.
Duke Cancer Institute's Dr. Neil Spector Explains Cancer Cells
During a recent talk at Teer House in Durham, North Carolina, oncologist Neil Spector, MD, of the Duke Cancer Institute explains in lay terms how cancer cells work.
Dr. Neil Spector Discusses Breast Cancer Heterogeneity
Neil L. Spector, MD, co-director, Experimental Therapeutics, Duke Cancer Institute, Duke University Medical Center, Durham, North Carolina, explains the need for an ample interpretation of breast cancer heterogeneity.
Read more at
Dr. Neil Spector Emphasizes the Importance of Studying Microenvironments
Neil L. Spector, MD, co-director, Experimental Therapeutics, Duke Cancer Institute, Duke University Medical Center, Durham, North Carolina, discusses the need for cancer researchers to investigate the entire system and tumor microenvironment.